Obesity and adipose tissue research Type 2 diabetes and insulin resistance Knee osteoarthritis Obstructive sleep apnea Non-alcoholic steatohepatitis (NASH) Key Findings from the Literature 01Phase 2: 24.2% mean weight loss at 48 weeks at highest dose 02Phase 3 TRIUMPH-4: 28.7% mean weight loss at 68 weeks 03Highest weight loss efficacy of any obesity pharmacotherapy in clinical trials to date 04Glucagon receptor agonism adds hepatic lipolysis absent from GLP-1-only agents 1 Independent third-party lab reports for this peptide
Benefits of Activating GLP-1 Receptors By increasing endogenous GLP-1 or using agonists that mimic GLP-1, we can activate GLP-1 receptors and obtain therapeutic benefits such as the following: Weight Control and Improved Satiety GLP-1 slows digestion, suppresses appetite, and enhances metabolism to promote one to achieve optimal weight
In this context, retatrutide provides a useful model for studying how incretin and glucagon pathway integration shapes adipose tissue responses, rather than isolating a single receptor axis
Unlike single-pathway peptides, Retatrutide is designed to engage multiple metabolic pathways
90 mg: -3.26%, p=0.0013), and plasma glucose (45 mg: -2.70, p=0.01
Ozempic has been a revolutionary drug for managing diabetes, but people also quickly realized that it had an interesting side effect: weight loss
